Background

Extracellular vesicles (EVs), once considered mere cellular debris, have emerged as critical mediators of intercellular communication, playing pivotal roles in both physiological processes and pathological conditions. These diverse nanoscale membrane-bound structures, including exosomes and microvesicles, are secreted by virtually all cell types and carry a rich cargo of proteins, lipids, and nucleic acids that reflect the state of their parent cells. This intrinsic biological function has positioned EVs as promising biomarkers for disease diagnosis, monitoring treatment efficacy, and predicting disease progression across a wide spectrum of medical conditions [1]. The rapid growth in EV research has greatly advanced our understanding of their biological role and potential clinical use. The ability to non-invasively sample and analyze patient-derived EVs offers an unparalleled opportunity for personalized medicine, moving beyond bulk tissue analysis to provide real-time insights into disease dynamics [2]. For instance, the presence of specific EV-encapsulated proteins or nucleic acids can serve as early indicators of disease onset, help to track the effectiveness of therapeutic interventions, or even predict patient response to particular treatments. This diagnostic and prognostic potential has fueled an intense drive to integrate EV analysis into routine clinical practice [3]. However, despite their immense promise, the widespread clinical application and comprehensive exploration of EVs face a significant bottleneck: the limitations of current isolation techniques. The inherent complexity and heterogeneity of biological fluids, coupled with the nanoscale dimensions of EVs, present formidable challenges. Several methods have traditionally been employed for EV isolation, each with its own set of advantages and disadvantages [4,5]. Ultracentrifugation (UC), long considered the gold standard, relies on differential centrifugation steps to progressively pellet EVs based on their size and density. While effective for isolating a broad range of EVs, UC is often criticized for its time-consuming nature, requirement for specialized equipment, potential for EV damage due to high G-forces, and the co-precipitation of contaminating proteins and aggregates, all of which necessitate skilled operators. Another common approach involves the use of size exclusion chromatography (SEC), which separates EVs based on their hydrodynamic radius as they pass through a porous matrix. SEC generally yields higher purity EV preparations and causes less mechanical stress compared to UC. However, SEC can suffer from lower recovery rates, particularly for smaller EVs, and can also be time-intensive, demanding careful column preparation and maintenance. Finally, commercial precipitation reagents offer a more convenient, often kit-based, approach to EV isolation. These methods typically involve the use of polymers that alter the solubility of EVs, causing them to aggregate and precipitate out of solution. While user-friendly and relatively rapid, precipitation methods can be prone to co-precipitation of non-EV components, leading to lower purity and potentially affecting downstream analyses. Furthermore, these reagents can sometimes interfere with the integrity or functionality of the isolated EVs.

Across all these established methods, recurring challenges persist for inconsistencies in yield and purity, compromises in EV integrity, and significant variations in reproducibility between laboratories. These issues are exacerbated when dealing with clinical samples of limited availability, such as those from pediatric patients, or when frequent, serial sampling is required for disease monitoring. The need for larger sample volumes, coupled with the labor-intensive nature of current techniques, often precludes their application in settings where only a few drops of blood are obtainable or where rapid turnaround times are crucial. The critical need for a more efficient, reliable, and accessible EV isolation method is underscored by the examples of disease-specific exosomal marker detection. Our laboratory’s investigations, including the identification of loss of LKB1 in transplant patients, SARS-CoV-2 spike protein in COVID-19 patients, and PD-L1 monitoring in immunotherapy recipients, all underscore the critical need for sensitive and accurate EV isolation from patient samples [6,7]. The lack of a robust, high-throughput, and low-volume compatible isolation technique has historically limited the potential for these exciting diagnostic and prognostic applications to translate from research laboratories into routine clinical practice.

This protocol is based on the understanding that an average EV content in human plasma is approximately 10¹⁰ per mL (ranging from 10⁸ to 10¹³ per mL) [8,9]. This method, which has been validated and is routinely used, directly tackles persistent limitations by offering a rapid, user-friendly, high-recovery EV isolation technique for accessible clinical samples like blood [6]. Such an advancement is not merely incremental; it is fundamental to unlocking the full potential of EV-centric diagnostics, monitoring, and therapeutic strategies, ultimately propelling the frontiers of biomedical research and its application in personalized medicine.